CD14+ CD15− HLA-DR− myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure

Gut

Volumn 67, Issue 6, 2018, Pages 1155-1167

  Bernsmeier, Christine ^a,b   Triantafyllou, Evangelos ^a,c,d   Brenig, Robert ^b   Lebosse, Fanny J ^c   Singanayagam, Arjuna ^a,c,d   Patel, Vishal C ^a   Pop, Oltin T ^a   Khamri, Wafa ^c   Nathwani, Rooshi ^c   Tidswell, Robert ^a   Weston, Christopher J ^d   Adams, David H ^d   Thursz, Mark R ^c   Wendon, Julia A ^a   Antoniades, Charalambos Gustav ^a,c,d  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; CYTOKINE; HLA DR ANTIGEN; INTERLEUKIN 6; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR; ANTIINFECTIVE AGENT; CD15 ANTIGEN; FUCOSYLTRANSFERASE; FUT4 PROTEIN, HUMAN; LIPOPOLYSACCHARIDE RECEPTOR;

ACUTE LIVER FAILURE; ADULT; ARTICLE; CHRONIC LIVER FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; MORTALITY; MYELOID-DERIVED SUPPRESSOR CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; ACUTE ON CHRONIC LIVER FAILURE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS;

ACUTE-ON-CHRONIC LIVER FAILURE; ADULT; ANTI-INFECTIVE AGENTS; CYTOKINES; FLOW CYTOMETRY; FUCOSYLTRANSFERASES; HLA-DR ANTIGENS; HUMANS; IMMUNE TOLERANCE; IMMUNOPHENOTYPING; LEWIS X ANTIGEN; LIPOPOLYSACCHARIDE RECEPTORS; LYMPHOCYTE ACTIVATION; MIDDLE AGED; MYELOID-DERIVED SUPPRESSOR CELLS; PHAGOCYTOSIS; POLYMERASE CHAIN REACTION; PROGNOSIS;

EID: 85026326292     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2017-314184     Document Type: Article

References (50)

1. Moreau R, Jalan R, gines P, et al. acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:14261437-1437.e9.
2. Bonnel AR, Bunchorntavakul C, Reddy Kr. immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol 2011;9:727-38.
3. Albillos A, Lario M, Álvarez-Mon M. cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol 2014;61:1385-96.
4. Bajaj JS, O'leary JG, Reddy Kr, et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: the north american consortium for the study of end-stage liver disease (nacSelD) experience. Hepatology 2012;56:2328-35.
5. Arvaniti V, D'amico G, Fede G, et al. infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010;139:1246-56.
6. Peranzoni E, Zilio S, Marigo I, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010;22:238-44.
7. Marvel D, Gabrilovich Di. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 2015;125:3356-64.
8. Bronte V, Brandau S, Chen SH, et al. recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 2016;7:12150.
9. Hoechst B, Ormandy La, Ballmaier M, et al. a new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces cD4(+)cD25(+) Foxp3(+) t cells. Gastroenterology 2008;135:234-43.
10. Arihara F, Mizukoshi E, Kitahara M, et al. increase in cD14+Hla-Dr -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother 2013;62:1421-30.
11. Hammerich L, Tacke F. emerging roles of myeloid derived suppressor cells in hepatic inflammation and fibrosis. World J Gastrointest Pathophysiol 2015;6:43-50.
12. Sander LE, Sackett SD, Dierssen U, et al. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med 2010;207:1453-64.
13. Janols H, Bergenfelz C, Allaoui R, et al. a high frequency of MDScs in Sepsis patients, with the granulocytic subtype dominating in gram-positive cases. J Leukoc Biol 2014;96:685-93.
14. Mougiakakos D, Jitschin R, Von Bahr L, et al. immunosuppressive cD14+Hla-Drlow/ neg iDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia 2013;27:377-88.
15. Yin J, Wang C, Huang M, et al. circulating cD14(+) Hla-Dr(-/low) myeloid-derived suppressor cells in leukemia patients with allogeneic hematopoietic stem cell transplantation: novel clinical potential strategies for the prevention and cellular therapy of graft-versus-host disease. Cancer Med 2016;5:1654-69.
16. Filipazzi P, Valenti R, Huber V, et al. identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007;25:2546-53.
17. Vuk-Pavlović S, Bulur Pa, Lin Y, et al. immunosuppressive cD14+Hla-Drlow/-monocytes in prostate cancer. Prostate 2010;70:443-55.
18. Wasmuth He, Kunz D, Yagmur E, et al. Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. J Hepatol 2005;42:195-201.
19. Antoniades CG, Berry Pa, Davies ET, et al. reduced monocyte Hla-Dr expression: a novel biomarker of disease severity and outcome in acetaminophen-induced acute liver failure. Hepatology 2006;44:34-43.
20. Berres ML, Schnyder B, Yagmur E, et al. longitudinal monocyte human leukocyte antigen-Dr expression is a prognostic marker in critically ill patients with decompensated liver cirrhosis. Liver Int 2009;29:536-43.
21. Berry Pa, Antoniades CG, Carey I, et al. Severity of the compensatory anti-inflammatory response determined by monocyte Hla-Dr expression may assist outcome prediction in cirrhosis. Intensive Care Med 2011;37:453-60.
22. Bajaj JS, O'leary JG, Reddy KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology 2014;60:250-6.
23. Bernsmeier C, Pop OT, Singanayagam A, et al. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MertK. Gastroenterology 2015;148:603-15.
24. Vergis N, Atkinson SR, Knapp S, et al. Patients with severe alcoholic Hepatitis given Prednisolone therapy who have high circulating levels of bacterial Dna are at increased risk for developing infections. Gastroenterology (Published Online First: 30 December 2016).
25. Pena OM, Pistolic J, Raj D, et al. endotoxin tolerance represents a distinctive state of alternative polarization (M2) in human mononuclear cells. J Immunol 2011;186:7243-54.
26. Sinha P, Okoro C, Foell D, et al. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 2008;181:4666-75.
27. Clària J, Stauber RE, Coenraad MJ, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology 2016;64:1249-64.
28. Nicodemus CF, Wang L, Lucas J, et al. toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy. Am J Obstet Gynecol 2010;202:608.e1-608.e8.
29. Ho V, Lim TS, Lee J, et al. tlr3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression. Oncotarget 2015;6:27252-66.
30. Le Noci V, Sommariva M, Tortoreto M, et al. reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor. Oncoimmunology 2016;5:e1234571.
31. Cardinaud S, Urrutia A, Rouers A, et al. triggering of tlr-3, -4, nOD2, and Dc-Sign reduces viral replication and increases t-cell activation capacity of HiV-infected human dendritic cells. Eur J Immunol 2017;47:818-29.
32. Deng T, Feng X, Liu P, et al. toll-like receptor 3 activation differentially regulates phagocytosis of bacteria and apoptotic neutrophils by mouse peritoneal macrophages. Immunol Cell Biol 2013;91:52-9.
33. Cheron A, Floccard B, Allaouchiche B, et al. lack of recovery in monocyte human leukocyte antigen-Dr expression is independently associated with the development of sepsis after major trauma. Crit Care 2010;14:r208.
34. Lin Y, Gustafson MP, Bulur Pa, et al. immunosuppressive cD14+Hla-Dr(low)/-monocytes in B-cell non-Hodgkin lymphoma. Blood 2011;117:872-81.
35. Laborde RR, Lin Y, Gustafson MP, et al. cancer vaccines in the world of immune suppressive monocytes (cD14(+)Hla-Dr(lo/neg) cells): the gateway to improved responses. Front Immunol 2014;5:147.
36. Lechner Mg, Liebertz DJ, Epstein AL. characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010;185:2273-84.
37. Lechner MG, Megiel C, Russell SM, et al. Functional characterization of human cd33+ and cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med 2011;9:90.
38. Maruyama A, Shime H, Takeda Y, et al. Pam2 lipopeptides systemically increase myeloid-derived suppressor cells through tlr2 signaling. Biochem Biophys Res Commun 2015;457:445-50.
39. Bunt SK, Clements VK, Hanson EM, et al. inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through toll-like receptor 4. J Leukoc Biol 2009;85:996-1004.
40. Van Rompaey N, Le Moine A. Myeloid-derived suppressor cells: characterization and expansion in models of endotoxemia and transplantation. Methods Mol Biol 2011;677:169-80.
41. Fontaine M, Planel S, Peronnet E, et al. S100a8/a9 mrna induction in an ex vivo model of endotoxin tolerance: roles of il-10 and iFnγ. PLoS One 2014;9:e100909.
42. Cazalis Ma, Lepape A, Venet F, et al. early and dynamic changes in gene expression in septic shock patients: a genome-wide approach. Intensive Care Med Exp 2014;2:20.
43. Medeiros Ai, Serezani Ch, Lee SP, et al. efferocytosis impairs pulmonary macrophage and lung antibacterial function via Pge2/eP2 signaling. J Exp Med 2009;206:61-8.
44. Yu L, Wang L, Chen S. Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med 2010;14:2592-603.
45. Sotolongo J, España C, Echeverry A, et al. Host innate recognition of an intestinal bacterial pathogen induces triF-dependent protective immunity. J Exp Med 2011;208:2705-16.
46. Wu J, Meng Z, Jiang M, et al. toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. Immunology 2010;129:363-74.
47. Davis CG, Chang K, Osborne D, et al. tlr3 agonist improves survival to secondary pneumonia in a double injury model. J Surg Res 2013;182:270-6.
48. Adams S. toll-like receptor agonists in cancer therapy. Immunotherapy 2009;1:949-64.
49. Chew V, Tow C, Huang C, et al. toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients. J Natl Cancer Inst 2012;104:1796-807.
50. Liu C, Zhang C, Lu H, et al. Poly(i:c) induce bone marrow precursor cells into myeloid-derived suppressor cells. Mol Cell Biochem 2011;358:317-23.